Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Editorial: Menopause and mental health.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Andrea K KnittelDepartment of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-4292-3255
Brooke W BullingtonDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-3341-087X
Andrew EdmondsDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0001-6768-0096
Catalina RamirezInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-0872-0307
Lisa RahangdaleDepartment of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-4444-7969
Genevieve Neal-PerryDepartment of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-1065-4898
Deborah Konkle-ParkerSchools of Nursing, Medicine and Population Health, University of Mississippi Medical Center, Jackson, Mississippi, USA.ORCID https://orcid.org/0000-0002-3319-8442
Deborah L JonesDepartment of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Elizabeth F TopperDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-5860-4913
Helen CejtinDepartment of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-9151-0203
Dominika SeidmanDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA.
Anjali SharmaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Adaora A AdimoraInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Michelle Floris-MooreInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0009-0007-9515-2857
Funding
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
National Institute of Child Health and Human Development K12HD103085National Institute of Child Health and Human Development P2CHD050924National Institute of Child Health and Human Development T32HD52468NCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01-HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01-HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01-HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01-HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01-HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01-HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01-HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NICHD NIH HHS K12 HD103085NICHD NIH HHS P2C HD050924NICHD NIH HHS R25 HD115514NICHD NIH HHS T32 HD052468NIMH NIH HHS P30 MH116867
6 · The paper itself
Abstract
objectiveThis study compares rates of menopausal hormone therapy (MHT) initiation between perimenopausal and postmenopausal women with moderate-severe vasomotor symptoms (VMS) with and without substance use in a longitudinal cohort of diverse US women with or without HIV.
methodsUsing menopause symptoms, hormone use, and substance use data from Women's Interagency HIV Study biannual visits (10/2008-9/2019), we compared initiation of and breaks in MHT among participants with moderate-severe VMS (1) with or without current substance use and (2) with or without ever using substances. We calculated unadjusted rates and adjusted rate ratios (RR) for demographics and health variables using Poisson regression.
resultsThe median age of participants (n = 1579) with moderate-severe VMS was 50 years old, with 73% living with HIV, and 68% identifying as Black. They reported ever using tobacco (76%), heavy alcohol (39%), cannabis (45%), and other drugs (43%). Few reported hormonal contraception (5%) or MHT (9%) during the study period. Hormone initiation (overall 3.53 per 100 person-years; 95% confidence interval [CI]: 2.93, 4.26) was less likely with current tobacco use (RR: 0.67, 95% CI: 0.45, 0.99) or ever using other drugs (RR: 0.61; 95% CI: 0.40, 0.91). Hormone breaks (overall 52.58 per 100 person-years [95% CI: 44.52, 61.90]) were not associated with substance use.
conclusionThe rate of MHT initiation was low and the rate of MHT breaks was high in this sample of perimenopausal and postmenopausal participants with moderate-severe VMS. Patients and providers might benefit from specific guidance regarding MHT use among individuals with current tobacco use and those who have ever used other drugs.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Substance use and menopausal hormone therapy: Treatment initiation and interruption among US women with and without HIV, 2008-2019. · full record | OpenQuestion